Prospective, Randomized Trial of Paclitaxel- versus Sirolimus- Eluting Stents for Treatment of Coronary Restenosis in Sirolimus-Eluting Stents Robert A. Byrne, Julinda Mehilli, Klaus Tiroch, Stefanie Schulz, Steffen Massberg, Karl-Ludwig Laugwitz, Albert Schömig, Adnan Kastrati Deutsches Herzzentrum & 1. Medizinische Klinik, Klinikum rechts der Isar, Technische Universität, Munich. Germany
12
Embed
Prospective, Randomized Trial of Paclitaxel- versus ...summitmd.com/pdf/pdf/100315_tct2009_1105.pdfof Paclitaxel- versus Sirolimus-Eluting Stents for Treatment of Coronary Restenosis
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Prospective, Randomized Trial of Paclitaxel- versus Sirolimus-Eluting Stents for Treatment of
Coronary Restenosis in Sirolimus-Eluting Stents
Robert A. Byrne, Julinda Mehilli, Klaus Tiroch, Stefanie Schulz, Steffen Massberg, Karl-Ludwig
Laugwitz, Albert Schömig, Adnan Kastrati
Deutsches Herzzentrum & 1. Medizinische Klinik, Klinikum rechts der Isar, Technische Universität, Munich. Germany
Prospective, Randomized Trial of Paclitaxel- versus Sirolimus-Eluting Stents for Treatment of
Coronary Restenosis in Sirolimus-Eluting Stents
Intracoronary Stenting and Angiographic Results: Drug Eluting
Stents for In-Stent Restenosis ISAR-DESIRE 2
ISAR DESIRE 2ISAR DESIRE 2
Study Organization
450 patients enrolled at two centres in Munich, Germany